Joseph M Collaco, Steven H Abman, Eric D Austin, Catherine M Avitabile, Angela Bates, Jeffrey R Fineman, Grace A Freire, Stephanie S Handler, Dunbar D Ivy, Usha S Krishnan, Mary P Mullen, Nidhy P Varghese, Delphine Yung, Melanie K Nies, Allen D Everett, Kanecia O Zimmerman, William Simmons, Hrishikesh Chakraborty, Gayane Yenokyan, Allison Newell-Sturdivant, Eric Christensen, Lindsay M Eyzaguirre, Daniel F Hanley, Erika B Rosenzweig, Lewis H Romer
Pulmonary hypertension (PH) is a significant health problem that contributes to high morbidity and mortality in diverse cardiac, pulmonary, and systemic diseases in children. Evidence-based advances in PH care have been challenged by a paucity of quality endpoints for assessing clinical course and the lack of robust clinical trial data to guide pharmacologic therapies in children. While the landmark adult AMBITION trial demonstrated the benefit of up-front combination PH therapy with ambrisentan and tadalafil, it remains unknown whether upfront combination therapy leads to more rapid and sustained clinical benefits in children with various categories of PH...
October 2023: Pulmonary Circulation